White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
Taiwan Issues Arrest Warrant for OnePlus CEO Over Alleged Illegal Recruitment Activities 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford 
China Considers New Rules to Limit Purchases of Foreign AI Chips Amid Growing Demand 
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
Chevron Set to Expand Venezuela Operations as U.S. Signals Shift on Oil Sanctions 
TSMC Set to Post Record Q4 Profit as AI Chip Demand Accelerates 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
Rio Tinto and BHP Agree to Explore Major Iron Ore Collaboration in Pilbara 
Microsoft Strikes Landmark Soil Carbon Credit Deal With Indigo Carbon to Boost Carbon-Negative Goal 
Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
One Percent Rule Checklist For Safer Forex Trading Risk 
DUBLIN, Ireland, April 13, 2017 -- Horizon Pharma plc (Nasdaq:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, announced today that its first-quarter 2017 financial results will be released on Monday, May 8, 2017. Following the announcement, Horizon's management will host a live conference call and webcast at 7:30 a.m. Eastern Time to review the Company's financial and operating results.
The live webcast and a replay may be accessed by visiting Horizon's website at http://ir.horizon-pharma.com. Please connect to the Company's website at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. Alternatively, please call 1-888-338-8373 (U.S.) or 973-872-3000 (international) to listen to the conference call. The conference ID number for the live call is 4624726. Telephone replay will be available approximately two hours after the call. To access the replay, please call 1-855-859-2056 (U.S.) or 404-537-3406 (international). The conference ID number for the replay is 4624726.
About Horizon Pharma plc
Horizon Pharma plc is a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. Horizon Pharma markets 11 medicines through its orphan, rheumatology and primary care business units. For more information, please visit www.horizonpharma.com. Follow @HZNPplc on Twitter or view careers on our LinkedIn page.
Contacts: Tina Ventura Senior Vice President, Investor Relations [email protected] U.S. Media: Geoff Curtis Senior Vice President, Corporate Communications [email protected] Ireland Media: Ray Gordon Gordon MRM [email protected]
